Percent of adolescents 13-17 years who have received the specified number of doses of the vaccine by the last day of the quarter

Data Source: North Dakota Immunization Information System (NDIIS)

¥: 1:1:2 adolescent vaccine series includes >=1 dose of Td or Tdap vaccine, >=1 dose of meningococcal conjugate (MCV4) vaccine and up-to-date with either 2 or 3 doses of human papillomavirus (HPV) vaccine
‡: rate for >=2 doses of MCV4 vaccine was assessed only for adolescents 16-17 years of age.
€: rate for series start and series up-to-date with Meningococcal B vaccine was assessed only for adolescents 16-17 years of age.